Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
← catalyst calendarNCT05400330 · readout ≤ 833 d
Sponsored by Lexeo Therapeutics (industry) · LXEO — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-08 | actual | When the study began enrolling |
| Primary completion | Nov 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2022-06-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer Disease
Intervention
- Biological: LX1001 — also filed as AAVrh.10hAPOE2
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment emergent adverse events
measured 260 weeks
Incidence of serious adverse events
measured 260 weeks
Permalink · LXEO's whole pipeline · Catalyst calendar · Every registered study · What changed